We are excited to announce our second publication of the year.
The study titled “Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy” has been published in Bioengineering & Translational Medicine.
This research introduces a spatial-hindrance-based Antibody Lock strategy, a proprietary technology developed by PrecisemAb Biotech, to create pro-Adalimumab. This mechanism significantly reduces interference from anti-idiotypic antibodies, one of the major factors that contribute to reduced efficacy in long-term antibody therapies.
The results demonstrate the potential of this strategy as a universal platform to convert existing therapeutic antibodies into next-generation prodrug forms—maintaining drug activity and half-life even in the presence of anti-Id antibodies.
We extend our congratulations to co-first authors Bo-Cheng Huang and Yu-Tung Chen, and to corresponding authors Dr. Chiao-Yun Chen and the late Professor Tian-Lu Cheng from the Drug Development and Value Creation Research Center at Kaohsiung Medical University.
We also express our sincere appreciation to all collaborating partners and supporting institutions whose contributions made this advancement possible.
This publication reinforces PrecisemAb’s commitment to designing antibody therapeutics that are not only targeted and effective but also safer for patients worldwide.
Together, we continue shaping the future of antibody innovation.
